I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

2022.11.03

GAITHERSBURG, MD . and SHANGHAI , Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

2022.10.05

GAITHERSBURG, MD . and SHANGHAI, China , Oct. 5, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will present new preclinical

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

2022.09.13

GAITHERSBURG, Md. and SHANGHAI , Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2